November 28, 2007 - WAYNE, PA - The Center for Professional Innovation &Education (CfPIE) is pleased to announce a new training program geared towards professionals involved with Pharmaceutical, Medical Device and Biotech Marketing and Advertising initiatives. The course, Marketing, Advertising and Promotion of Pharmaceuticals and Medical Devices is scheduled for January 14 &15, 2007 at The Desmond Hotel &Conference Center in Malvern, PA. This two-day program will give participants a comprehensive overview of the regulatory requirements binding Pharmaceutical and Medical Device marketers and insights on how to develop and maintain a successful marketing/advertising plan.

Pharmatest Services a full-service Contract Research Organization (CRO) announces today that it has signed new customer contracts valued at nearly US$700,000 during the first quarter of 2008 with multiple leading biopharmaceutical companies worldwide.

The new contracts include research projects in the therapeutic areas of oncology, women's health and inflammation (osteoarthritis). Services to be provided are preclinical lead validation and efficacy studies for new drug compounds.

Biovian's CEO, Mr Sakari Heyno, will be available for the face to face partnering offered at the conference. To request a meeting please contact Mr. Sakari Heyno at sakari.heyno@biovian.com or at the BIO 2008 conference partnering website.

ABOUT BIOVIAN

Biovian is a one-stop-shop in cGMP contract manufacturing of biopharmaceuticals covering services from early development to aseptic fill and finish. Biovian's inspected 1600 m² cGMP facilities contain EU grade A, B, C and D class clean rooms and warehouse under full quality control as well as extensively equipped laboratories.

Biovian cGMP services include:

• Fermentation and cell culture
• Viral vector production
• Protein purification
• Formulation
• Fill and finish
• Lyophilization
• Analytical quality control services

Biovian complementary services include:

• Process development
• Analytical development
• Proteins for research purposes
• Diagnostic reagents

Pharmatest Services Ltd, a Finnish pharmaceutical contract research organization, has developed novel in vitro human bone cell assays as research tools for pharmaceutical companies developing new therapies against osteoporosis and cancer-induced bone disease. These assays can be used to test vast amounts of new drug compounds for their effects on bone formation and bone resorption in vitro. "Our bone cell assays are unique in a sense that they are based on the use of human bone cells (osteoclasts and osteoblasts). All similar previously commercially available models have either been performed in animals, or based on the use of rodent cells", says Pharmatest CEO and Scientific Director Dr.

Sales grow to CHF198.3 million - up 17.0% in local currencies and 15.5% in CHF respectively Operating profit up 29.9%, net income up 37% Operating margin rises sharply to 36.5%, net income margin now at 32.3% Prosposed increase in dividend by 50% to CHF3.00 per share Positive trend in demand and systematic expansion of the portfolio and capacity promise continued growth in 2008 The Bachem Group (SWX: BANB) today announced results for the business year 2007. The company achieved a new sales record of CHF198.3 million in 2007. Compared with 2006, sales grew by 17.

Action Pharma A/S and Bachem (SWX: BANB) today announced their cooperation on AP214, Action Pharma's lead compound, about to enter Phase 2 clinical trials in post-surgical organ failure. Since 2002, Bachem has supported Action Pharma by producing the peptide active ingredient of this drug candidate, by analytical method development, analytical method validation as well as by regulatory services. For the upcoming Phase 2 clinical trial, Bachem also supplies finished dosage forms under its Clinalfa® brand. Prof. Søren Nielsen, CEO and Co-founder of Action Pharma, commented: "For years, Bachem has supported us as a full-service provider on the active ingredient of our lead compound, a very valuable contribution for our start-up company.

IDBS, a provider of drug discovery data management solutions, today announced that the global pharmaceutical company Boehringer Ingelheim (Ingelheim, Germany) has purchased IDBS' predictive modelling technology PredictionBase for use at its Biberach an der Riss research site. Scientists at the Biberach facility, where research into diseases of the Central Nervous System (CNS), metabolic diseases and respiratory diseases is centred, will use PredictionBase to build and deploy and distribute predictive ADME QSAR models using existing data. Boehringer Ingelheim sought a solution that would help reduce the effort required for scientists to perform prediction manually, while also efficiently distributing valuable drug discovery knowledge throughout the company.

Antimicrobial peptides Plants produce a high number of various antimicrobial peptides such as defensins, thionins, lipid transfer proteins and snakins. It had been recently found that these classes of genes account of approximately 2% - 3% of the gene repertoire of each model species (Egorov et al., 2005, Peptides 26, 2064 - 2073; Silverstein et al., 2007, Plant J. 51, 262 - 280; Rossi et al., 2008, J. Pharm. Sci. 97, 1060 - 1070). Related antibodies against plant proteins: Anti-hellethionin - H13H-1 New! Anti-hellebrin - H14H-1 New! Highlights in protein phosphorylation in chloroplasts Two thylakoid protein kinases (STN7/Stt7) and (STN8/Stll) control the phosphorylation of light-harvesting antenna and photosystem II proteins (D1, D2, CP43, PsbH) (Bellafiore et al.

IDBS is proud to announce the upcoming releases of E-WorkBook Suite 8.0, ActivityBase 7.0 and ActivityMart 3.0. The forthcoming releases are to be delivered in early 2008 as part of IDBS' continued commitment to developing and integrating its industry-leading product suites. ActivityBase is IDBS' flagship product and since its inception has become the industry-standard screening solution, employed by over 75% of the world's leading biotechnology and pharmaceutical companies. Enhancements to ActivityBase 7.0 include simplified plate creation, time savings in results processing and report generation and support for chemical tautomer searching.

IDBS, provider of data management, analysis and decision support software, is proud to report double-digit revenue growth and profitability for 2007 despite increasingly challenging market conditions. Sales revenues have increased by almost 50% since 2005, on the back of major developments to core product lines such as the ActivityBase Suite. Much of the revenue also coming from existing customers who have invested in new technologies such as the E-WorkBook Suite, with a consistently high level of renewals and substantial market expansion to new customers. "The excellent sales performance over the past few years reflects the innovations we have made in the management of discovery data," commented Neil Kipling, founder and CEO of IDBS.

LAB Research Hungary has over 30 years of toxicology experience and offers the leading pharmaceutical and biotechnology companies the complete range of pre-clinical services, from acute to carcinogenicity. A newly completed building increases the capacity of the facility to 62 state-of-the-art rodent animal rooms with its large animal housing increasing to 480, all in full compliance with EU animal housing requirements. In addition, this facility specializes in ecotoxicology, offering technical solutions that address regulatory and environmental issues. It is an authorized REACH Ready facility. Today, LAB Research Hungary is home to scientific and business teams that blend significant expertise from Europe, North America and the Far East.

BioUETIKON Ltd, the new biotech services division of Chemie Uetikon (CU) and Chemie + Papier Holding (CPH), will be officially launched on Monday 28th April in Dublin, Ireland by the Taoiseach, Mr. Bertie Ahern TD. BioUETIKON Ltd provides upstream/downstream development and GMP CMO services to the biopharmaceutical, medical device and related industries. Located in a flexible, high quality facility approximately 15 minutes from Dublin Airport on the Dublin City University (DCU) campus, BioUETIKON is ideally situated to serve international and local clients. As a DCU spin-out, BioUETIKON had over 10 years' experience of biopharmaceutical production prior to CPH investment in late 2006.

Neurofit is pleased to announce its participation at BIO-SQUARE 2008 from March 12 to 14, 2008, Basel, Switzerland.

Neurofit is a preclinical CRO offering in vitro and in vivo drug screening services in the area of pain, psychiatry, neurology, multiple sclerosis and oncology. For more information and details of our screening tests, please visit our website at http://www.neurofit.com.

If you are attending the meeting, our CEO, Dr. Frank Sams-Dodd will be very pleased to meet with you to discuss possible areas of collaboration or alternatively contact Frank directly (sams-dodd@neurofit.com) to set-up a time for a telephone conference.

Leading provider of software solutions to the life sciences industry increases customer satisfaction with improved call management and customer self-service. IDBS, the independent software vendor (ISV) specialising in drug discovery solutions, has selected Hornbill's Supportworks to provide support services to customers of its data management software. The IDBS customer support team will be using Hornbill's solution to support thousands of users at over 250 companies using its software. Using Supportworks, IDBS expects improved customer satisfaction through a more efficient customer service. IDBS selected Supportworks from a shortlist of five other suppliers for the solution's out-of-the-box functionality, open integration capabilities and ease of configuration.

BioUETIKON, a bioprocess development, optimiztion and GMP production CMO will be attending the Biosquare 2008 conference in Basel, Switzerland from the 12th to the 14th of March 2008 to introduce its range of services ahead of the company's official launch in April 2008.

Biosquare is one of the most prominent events in the pharmaceutical and life science industry calendar, playing host to some 800 market-leading companies from 34 different countries such as JBA, Ernst & Young, and Swiss Biotech. The three-day event will feature a full program including panels and workshops led by corporate executives and biotech experts.

Mike Mulcahy, Managing Director, BioUETIKON will be available for one-to-one meetings at the conference, where he will represent BioUETIKON's commitment to the pharmaceutical and life sciences through their competitive range of bioprocess development, scale up and GMP production services.

With nine years of experience in organic synthesis and medicinal chemistry, TriMen Chemicals assists its clients in shortening the time and lowering the cost of the early stages of the drug discovery process. Our objective is to create a long-term relationship with our customers by supplying excellent value-for-money services. LABORATORY-SCALE DRUG AND CHEMICAL SYNTHESIS To help our partners in their drug discovery and chemical development efforts, TriMen provides custom synthesis of compounds for multiple drug discovery applications. TriMen personnel provide extensive experience in synthesis, synthetic route design, and execution.

ALSACHIM is an independent contract research and development organisation that specialises in stable isotope-labelled compounds, metabolites and pharmaceutical related substances, and rare chemicals for medicinal chemistry research and analytical purposes. We supply our products to customers all over the world, spread throughout the chemical discipline including the pharmaceutical and biotech industry, clinical and bio-analytical CROs and related research institutions. ALSACHIM&squo;s team of highly experienced scientists can effectively support your research with services that include custom synthesis and chemical development complemented by integrated state-of-the-art analytical services (NMR, MS, HPLC-MS).

Indigo Biosciences is a preclinical contract research organization, serving clients involved in pharmaceutical and nutraceutical R&D, biotechnology, and related sectors. We offer reliable, high quality, and confidential screening services for drug discovery / drug development, characterization of active ingredients, and molecular toxicology. We specialize in evaluation of the effects of small molecules on nuclear receptors, a major class of therapeutic drug targets. Indigo Biosciences offers a quality alternative to the development of expensive in-house analyses outside your company's specific expertise.

Oritavancin is an investigational glycopeptide antibiotic currently being developed by Targanta Therapeutics for the treatment of serious gram-positive bacterial infections. It was originally discovered and developed by scientists at Eli Lilly as a potential replacement for vancomycin. Targanta Therapeutics acquired worldwide rights to oritavancin from Intermune Inc in 2005, to which the drug had previously been licensed in 2001. In February 2008, Targanta Therapeutics filed an NDA with the US FDA for use of oritavancin in the treatment of complicated skin and soft tissue infections (cSSIs). Other potential indications for this new antibiotic include bacteraemia and osteomyelitis.

In partnership with Novartis Pharma, Idenix Pharmaceuticals is developing valtorcitabine (L-deoxycytidine) as part of a fixed-dose combination therapy with telbivudine for the treatment of chronic hepatitis B virus (HBV) infection. Like telbivudine, valtorcitabine is a highly specific and selective inhibitor of HBV replication in vitro. It specifically targets HBV DNA polymerase without inhibiting human cellular polymerases. "At a dose of 900mg/day, valtorcitabine achieved a 99.9% reduction in viral load." Valtorcitabine is still in early-stage development, where it is being investigated in proof-of-concept trials in combination with telbivudine.

Roche/Genentech's pertuzumab is a humanised monoclonal antibody (MAb) to the HER2 receptor that is currently in phase III development for the treatment of advanced breast cancer. Progression to phase III clinical trials comes on the back of encouraging phase II data, which suggest that the addition of pertuzumab to trastuzumab (Herceptin) can benefit breast cancer patients no longer responsive to standard therapy (trastuzumab plus chemotherapy). HER DIMERISATION INHIBITORS (HDIs) ‐ A NEW THERAPEUTIC CLASS The HER family of transmembrane tyrosine kinase receptors, most especially HER2, have been identified as an important therapeutic target in breast cancer.